CORAL GABLES, Fla., May 10, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2017.
“We continue to work diligently toward the completion of enrollment in our Firdapse® LEMS and CMS clinical trials,” said Patrick J. McEnany, Chief Executive Officer of Catalyst. “We were also pleased to announce positive top-line results from a proof-of-concept trial for Firdapse as a potential treatment for myasthenia gravis patients that are MuSK antibody positive. We remain committed to the rest of our scientific pipeline and continue to seek ways to leverage our CPP-115 and vigabatrin programs.”
